NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. - Wikidata - wikimedia - TriplyDB

NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy.

NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy.

http://www.wikidata.org/entity/Q37170509

about

From Inflammation to Prostate Cancer: The Role of Inflammasomes The Nucleotide Oligomerization Domain-Like Receptors in Kidney Injury Acute and chronic kidney injury in nephrolithiasis Nephropathy in dietary hyperoxaluria: A potentially preventable acute or chronic kidney disease Cytotoxicity of crystals involves RIPK3-MLKL-mediated necroptosis Chronic Nephropathy from Dietary Hyperoxaluria: Sustained Improvement of Renal Function after Dietary Intervention Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL/6 mice.An animal model of type A cystinuria due to spontaneous mutation in 129S2/SvPasCrl mice.Distinguishing characteristics of idiopathic calcium oxalate kidney stone formers with low amounts of Randall's plaque.The emerging role of the inflammasome in kidney diseases Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis.Activation of the NLRP3 inflammasome in association with calcium oxalate crystal induced reactive oxygen species in kidneys.An update on the role of the inflammasomes in the pathogenesis of kidney diseases.Impact of nephrolithiasis on kidney function.Kidney Disease in Adenine Phosphoribosyltransferase Deficiency.A test of the hypothesis that oxalate secretion produces proximal tubule crystallization in primary hyperoxaluria type I.Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis.Dendritic Cells and Macrophages: Sentinels in the Kidney.Enteric hyperoxaluria: an important cause of end-stage kidney disease.The NLRP3 inflammasome in kidney disease and autoimmunity.The in vivo evidence for regulated necrosis.Inflammasomes in the urinary tract: a disease-based review.Oxalate, inflammasome, and progression of kidney disease Loss of Cystic Fibrosis Transmembrane Regulator Impairs Intestinal Oxalate Secretion.Genetic, pathophysiological, and clinical aspects of nephrocalcinosis.Crystal nephropathies: mechanisms of crystal-induced kidney injury.Hyperoxaluria Requires TNF Receptors to Initiate Crystal Adhesion and Kidney Stone Disease.Oolong tea: A critical review of processing methods, chemical composition, health effects, and risk.NLRP3 Localizes to the Tubular Epithelium in Human Kidney and Correlates With Outcome in IgA Nephropathy Characterization of calcium oxalate crystal-induced changes in the secretome of U937 human monocytes.Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease.siRNA Therapeutics for Primary Hyperoxaluria: A Beginning.Is the inflammasome a potential therapeutic target in renal disease?Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis: clinical and molecular characteristics.Long non-coding RNA CHCHD4P4 promotes epithelial-mesenchymal transition and inhibits cell proliferation in calcium oxalate-induced kidney damage.Summary of ISN Forefronts Symposium 2015: ‘Immunomodulation of Cardio-Renal Function’.Impact of Regular or Extended Hemodialysis and Hemodialfiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease.Anticancer Drug-Induced Acute Kidney Injury.IL-1 Inhibition and Vascular Function in CKD.Glycine Amidinotransferase (GATM), Renal Fanconi Syndrome, and Kidney Failure.

P2860

Q26739947-439E75A9-23C2-4CFB-A24C-916AD7440716 Q26740429-4A5FD3F5-E4C7-46D2-AE89-9491B6C2F8FA Q26827230-74274F63-D0E6-46EF-AB72-CB262E8C4481 Q26865804-E8E2C2A2-AFE4-4CC0-97BA-63A44D368574 Q27335987-17B623E0-C49B-48E8-9A00-FF6AE60551D5 Q33585896-607E3DE2-3902-4115-A9E9-687D834B0197 Q33891513-7115AF01-28FA-40E3-9B89-00E5060CBBCB Q33927702-53EAA600-25A1-4A06-AE31-69F02B97059F Q34292839-6B5DFF2A-CE98-4437-ACF7-9C8A4A3AE688 Q34307043-52EEB60C-A9D8-44B9-AEE5-E3AAA6D4DAED Q34721833-105C94DA-7D8E-4A99-91EB-D02C8267ACCD Q35528594-0010715A-7EA6-4952-B1E4-1EFD6079F1DD Q35692937-ED4EDF75-6E5E-483D-B06E-330672021739 Q35758325-38E60387-9DFB-4320-9FAF-262F67AE281E Q36762992-E5DED71E-31AE-45E1-849C-BC837405446E Q37439745-49F89657-F7F5-44F7-8BD2-C3748277BC77 Q38206875-EC407D9B-1449-4F77-B606-895F40C383FF Q38310937-A2078A42-EF76-44D3-AD61-B07245EB35BD Q38363406-7A5060A7-15A5-4B81-9698-BF6CA929D9A2 Q38787339-AB8962FF-2E45-44CA-91DB-719B5351E414 Q38809791-6EB65A5E-FE83-403A-8F09-84BC3056AC4F Q38832656-8A0B88A9-915A-477F-89AC-4EFDE5E6D779 Q38837256-25727183-671A-48E9-950A-86AC954A6DC4 Q38851904-39530610-3722-41D9-9537-5F38AE000361 Q38949044-C1F6AD52-7273-4F73-9195-C1DC2E845F1B Q39144172-9C33DA36-3591-437E-ABE5-6B739B5CE0C5 Q39405553-7FCE8C88-57D7-4351-BBE1-5F782022210B Q39415415-A1CC42FF-8270-4E2E-99B4-A335D949C8A9 Q39839285-6780A8BA-2929-4273-BF4F-239D5003AC68 Q40112363-5028252C-B47A-4B0D-8672-F0B314C92DC2 Q41814998-B2549B70-E72E-41D1-BFFD-26AFC4F7674A Q41840275-A47C52AA-FDCC-473C-9352-A0D9BD25CBBD Q41934684-BBE8601E-F43C-4B01-9764-27F80DB12F88 Q41996768-3548B192-F46F-4101-BAA3-E46EE9DA71D3 Q46405828-9C43935E-CD23-443E-858D-EBC1D83C5DE2 Q47118419-A5C57DA9-5648-4445-8E08-33C7A9533436 Q47150470-9223DA2A-1D5B-482E-B2EE-66A5071896EE Q47261056-6B8BFDAB-FA69-434A-98E0-A71922669375 Q48040831-30C5E138-46B9-44A0-963F-D359E4074DBB Q52589122-A1953703-CC46-463C-B0B3-0D6CADDA3322

P2860

NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy.

http://www.wikidata.org/entity/Q37170509

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 June 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

NALP3-mediated inflammation is ...... ailure in oxalate nephropathy.

@en

NALP3-mediated inflammation is ...... ailure in oxalate nephropathy.

@nl

type

label

NALP3-mediated inflammation is ...... ailure in oxalate nephropathy.

@en

NALP3-mediated inflammation is ...... ailure in oxalate nephropathy.

@nl

prefLabel

NALP3-mediated inflammation is ...... ailure in oxalate nephropathy.

@en

NALP3-mediated inflammation is ...... ailure in oxalate nephropathy.

@nl

P1433

Q37170509-F020F62D-086D-4E02-9EBA-879140916A1D

P1476

Q37170509-F64F11DF-4D5B-427C-AC6C-0FB323A28FE4

P2093

Q37170509-17E3C178-938C-4F84-81BD-EA68FF3AED01

Q37170509-3590ADDB-0C93-4ABF-9F73-AD00F9310950

Q37170509-7F4925DD-90E9-4193-BCDF-5C7170B2E9E2

Q37170509-9C7F0348-A846-4A97-8EA5-16530C843A97

Q37170509-C8918D52-4100-4B2F-B7F8-1ABEE798E6E1

Q37170509-EE8B8267-3F74-4227-A520-2C696CC6FA05

Q37170509-F9A127B8-EF23-4BDB-B350-F31D15BEAC52

Q37170509-FFAA2AC6-65B7-426F-AA95-104297CD183C

P2860

Q37170509-11B41028-582D-4B72-BBA4-DF7AC09F3C26

Q37170509-187428C5-4A20-47E7-B479-D9A36F7A2A47

Q37170509-203B6191-4C88-435B-8DB6-9D56B757F023

Q37170509-21FC826B-AE25-41E8-8DB8-0826AF310992

Q37170509-29F5ABF8-6EBB-421A-AB54-A194D4937475

Q37170509-3277020F-3ECA-48F9-AF9B-5406578AC41A

Q37170509-34F81DB0-97A3-4AB4-8219-7ED77F002012

Q37170509-3BD3BE11-1A66-4F4F-8B25-8D1FFE7CF55F

Q37170509-4105F27D-7DA8-4BFC-BF0E-0514E8F1CBDD

Q37170509-413BA0F6-95A6-43A0-BB53-674E61AE1DAF

P2888

Q37170509-85E9B3E7-E94A-4966-93B3-4A7A2A936C19

P304

Q37170509-CDDE12CD-8779-407F-9718-B3C6AA1BE4CF

P31

Q37170509-E258AB1B-E14C-4582-9285-64D69A9A5B65

P356

Q37170509-511602AE-65A3-4148-AC86-CFF91DE1BE61

P407

Q37170509-8880EBFD-8FE2-4B05-BA4A-AD9BDA1AFBB1

P433

Q37170509-21429996-8F0A-46FA-97AE-B50C68B8E437

P478

Q37170509-4F58431E-9DAA-4C92-A35F-245DCFFB5ED9

P577

Q37170509-7405C39C-4181-471A-9E3E-0FA7F6671922

P5875

Q37170509-AE481C9F-1C4F-474B-9325-97DA41AFF873

P6179

Q37170509-4CC5F6A4-457B-47C2-9DAE-FF1ADF3D17F0

P698

Q37170509-F55A0E4B-0F3D-4E91-B919-4E04D7208F67

P921

Q37170509-1FB906A9-7599-4C49-9062-4C9B4670DC78

P932

Q37170509-819C78ED-0024-41D1-A3D5-48A043E99A1B

P356

P1433

Kidney International

P1476

NALP3-mediated inflammation is ...... ailure in oxalate nephropathy.

@en

P2093

Felix Knauf

http://www.w3.org/2001/XMLSchema#string

Gilbert W Moeckel

http://www.w3.org/2001/XMLSchema#string

Ignacio Granja

http://www.w3.org/2001/XMLSchema#string

Insa M Schmidt

http://www.w3.org/2001/XMLSchema#string

John R Asplin

http://www.w3.org/2001/XMLSchema#string

Peter S Aronson

http://www.w3.org/2001/XMLSchema#string

Rachel J David

http://www.w3.org/2001/XMLSchema#string

Richard A Flavell

http://www.w3.org/2001/XMLSchema#string

P2860

The Nalp3 inflammasome is essential for the development of silicosis

Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica

Gout-associated uric acid crystals activate the NALP3 inflammasome

Net intestinal transport of oxalate reflects passive absorption and SLC26A6-mediated secretion

Acute oxalate nephropathy after ingestion of star fruit.

Crystal-induced acute renal failure.

A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria.

The NLRP3 inflammasome promotes renal inflammation and contributes to CKD.

An inflammasome-independent role for epithelial-expressed Nlrp3 in renal ischemia-reperfusion injury

Stones from bowel disease.

P2888

P304

895-901

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/KI.2013.207

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

84

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

237059160

http://www.w3.org/2001/XMLSchema#string

P6179

1010733973

http://www.w3.org/2001/XMLSchema#string

P698

23739234

http://www.w3.org/2001/XMLSchema#string

P921

P932

3772982

http://www.w3.org/2001/XMLSchema#string